All In Biotech

Drug Trial Radar · NCT07928661

Effect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 Diabetes

Open Label Evaluator Blind,The Effect of Proliverenol Supplementation on the Visceral Adiposity Index, HOMA-IR, C-Peptide, and Controlled Attenuation Parameter (CAP) in Patients With Type 2 Diabetes at Dr. Mohammad Hoesin General Hospital in Palembang.

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jul 29, 2026

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Universitas SriwijayaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 30 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to determine whether Proliverenol supplementation can improve liver fat levels and blood sugar control in patients with type 2 diabetes. Participants will be divided into two groups: one group will receive Proliverenol with standar therapy of DM, and the other only receive standar therapy of DM. The study will last for 12 weeks, and participants will undergo blood tests and liver examinations."

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • ProliverenolDrug

    This is the first study to evaluate Proliverenol specifically in patients with type 2 diabetes."

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the Visceral Adiposity Index (VAI) from baseline to week 12Time frame: Baseline and week 12
  2. Change in HOMA-IR from baseline to week 12Time frame: Baseline and week 12
  3. Change in C-Peptide from baseline to week 12Time frame: Baseline and week 12
  4. Change in Controlled Attenuation Parameter (CAP) from baseline to week 12Time frame: Baseline and week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Sriwijaya Palembang

    Palembang, South Sumatera, Indonesia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.